Drug Approval | December 28, 2021
Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The drug will be marketed under the brand name Molnaflu
This product will be manufactured at Lupin's Goa facility in India
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Flattish volume growth and subdued new launches were key factors for last month
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated
